Researchers have uncovered a redundancy in the immune system that could make future mRNA cancer vaccines far more potent than previously understood. The finding suggests cancer vaccines are even more resilient than scientists believed, with built-in backup mechanisms that keep working even when key immune cells fail to show up.
A team at Washington University School of Medicine in St. Louis published the discovery in Nature, revealing that mRNA cancer vaccines activate the immune system through multiple pathways simultaneously. The work comes as the same technology that created COVID-19 vaccines is being repurposed to fight melanoma, lung cancer, bladder cancer, and other malignancies in early human trials.
In experiments with mice, researchers deleted specific immune cells they thought were essential for the vaccine's success. The vaccine worked anyway. A backup immune cell type stepped in and generated powerful tumor-fighting responses.
The traditional understanding held that dendritic cells called cDC1 were the primary drivers of anti-tumor immunity after mRNA vaccination. These cells are well-documented for preparing T cells to attack virus-infected tissue. But when researchers eliminated cDC1 cells from vaccinated mice, tumors still disappeared.
Instead, a related dendritic cell called cDC2 activated T cells and cleared sarcomas. Mice lacking cDC2 cells mounted immune responses too. Even more striking, mice with both cell types intact generated even stronger responses, suggesting the two pathways work in concert.
Kenneth M. Murphy, the senior author and Eugene Opie Centennial Professor of Pathology and Immunology at WashU Medicine, described the implications. "By dissecting which immune cells are involved and how they coordinate the response, we're offering vaccine developers some additional mechanistic insights to consider in their goal of optimizing these vaccines against tumor proteins."
The research also exposed how cDC2 cells accomplish their task. Unlike cDC1 cells, which directly produce vaccine proteins from mRNA instructions, cDC2 cells rely on a hand-off mechanism. Other cells read the mRNA, manufacture the proteins, and transfer the protein fragments to cDC2 cells through a known process called cross dressing. The cDC2 cells then display those fragments to activate T cells.
This discovery matters for practical vaccine development. Understanding multiple activation pathways gives manufacturers new targets for improving formulations and dosing regimens. It could also explain why some patients respond better to mRNA vaccines than others and guide strategies to boost effectiveness across populations.
William E. Gillanders, co-corresponding author and Mary Culver Professor of Surgery at WashU Medicine, underscored the clinical potential. "This work uncovers a new way mRNA vaccines engage the immune system through both cDC1 and cDC2, which helps explain their power and gives researchers concrete targets for making future mRNA cancer vaccines more effective."
The T cells activated by each dendritic cell subtype carry different molecular signatures, hinting that they may perform complementary roles in tumor suppression. That distinction could allow researchers to fine-tune vaccines to maximize both pathways and generate more durable anti-tumor immunity.
Author Jessica Williams: "This isn't just another incremental finding about how vaccines work, it's a blueprint for making them stronger that vaccine developers didn't know existed."
Comments